Antibody validation: a view from the mountains.

Validation of antibodies and other protein binders is a subject of pressing concern for the research community and one which is uppermost in the minds of all who use antibodies as research and diagnostic reagents. Assessing an antibody's fitness for purpose includes accurate ascertainment of its target specificity and suitability for the envisaged task. Moreover, standardised procedures are essential to guarantee sample quality in testing procedures. The problem of defining precise standards for antibody validation has engendered much debate in recent publications and meetings, but gradually a consensus is emerging. At the 8th Alpbach Affinity Proteomics workshop (March 2017), a panel of leaders in the antibody field discussed suggestions which could bring this complex but essential issue a step nearer to a resolution. 'Alpbach recommendations' for best practice include tailoring binder validation processes according to the intended applications and promoting greater transparency in publications and in the information available from commercial antibody developers/providers. A single approach will not fit all applications and end users must ensure that the reported validation holds for their specific requirements, highlighting the need for adequate training in the fundamentals of antibody characterisation and validation across the user community.

[1]  Dan S. Tawfik,et al.  Antibody Multispecificity Mediated by Conformational Diversity , 2003, Science.

[2]  Peter Woollard,et al.  A Community Standard Format for the Representation of Protein Affinity Reagents* , 2009, Molecular & Cellular Proteomics.

[3]  Henning Hermjakob,et al.  Minimum information about a protein affinity reagent (MIAPAR) , 2010, Nature Biotechnology.

[4]  Emma Lundberg,et al.  A proposal for validation of antibodies , 2016, Nature Methods.

[5]  Zoltan Nusser,et al.  Specificity of Immunoreactions: The Importance of Testing Specificity in Each Method , 2008, The Journal of Neuroscience.

[6]  B. Jensen,et al.  Ten commercial antibodies for alpha-1-adrenergic receptor subtypes are nonspecific , 2009, Naunyn-Schmiedeberg's Archives of Pharmacology.

[7]  Franklin Peale,et al.  Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site , 2009, Science.

[8]  C. Begley,et al.  Drug development: Raise standards for preclinical cancer research , 2012, Nature.

[9]  U. Landegren,et al.  Solid-phase proximity ligation assays for individual or parallel protein analyses with readout via real-time PCR or sequencing , 2013, Nature Protocols.

[10]  A. Hyman,et al.  Antibody Validation in Bioimaging Applications Based on Endogenous Expression of Tagged Proteins. , 2017, Journal of proteome research.

[11]  U. Landegren,et al.  Analytically Sensitive Protein Detection in Microtiter Plates by Proximity Ligation with Rolling Circle Amplification. , 2017, Clinical chemistry.

[12]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[13]  Carl-Magnus Clausson,et al.  Insufficient antibody validation challenges oestrogen receptor beta research , 2017, Nature Communications.

[14]  Andreas Plückthun,et al.  Getting to reproducible antibodies: the rationale for sequenced recombinant characterized reagents. , 2015, Protein engineering, design & selection : PEDS.

[15]  S. Lazic,et al.  A call for transparent reporting to optimize the predictive value of preclinical research , 2012, Nature.

[16]  Maryann E Martone,et al.  The Resource Identification Initiative: a cultural shift in publishing , 2015, Brain and behavior.

[17]  U. Landegren,et al.  Protein detection using proximity-dependent DNA ligation assays , 2002, Nature Biotechnology.

[18]  A. Šimundić,et al.  Special issue: Responsible writing in science , 2012 .

[19]  James S Trimmer,et al.  Developing high-quality mouse monoclonal antibodies for neuroscience research - approaches, perspectives and opportunities. , 2016, New biotechnology.

[20]  Karl-Friedrich Becker,et al.  Reverse Phase Protein Arrays—Quantitative Assessment of Multiple Biomarkers in Biopsies for Clinical Use , 2015, Microarrays.

[21]  Stephen J. Smith,et al.  Array Tomography: A New Tool for Imaging the Molecular Architecture and Ultrastructure of Neural Circuits , 2007, Neuron.

[22]  F. Collins,et al.  Policy: NIH plans to enhance reproducibility , 2014, Nature.

[23]  John P A Ioannidis,et al.  Improving Validation Practices in “Omics” Research , 2011, Science.

[24]  Jan-Eric Litton,et al.  Quality Matters: 2016 Annual Conference of the National Infrastructures for Biobanking. , 2017, Biopreservation and biobanking.

[25]  C. Drevon,et al.  Irisin – a myth rather than an exercise-inducible myokine , 2015, Scientific Reports.

[26]  Andreas Plückthun,et al.  Reproducibility: Standardize antibodies used in research , 2015, Nature.

[27]  Matthew H. Brush,et al.  The Resource Identification Initiative: A cultural shift in publishing , 2015, F1000Research.

[28]  M. Cristina Cardoso,et al.  Nanobodies and recombinant binders in cell biology , 2015, The Journal of cell biology.

[29]  David J Sherman,et al.  Minimum information requirements: neither bandits in the Attic nor bats in the belfry. , 2009, New biotechnology.

[30]  Rasel A. Al-Amin,et al.  A myopic perspective on the future of protein diagnostics , 2017, bioRxiv.

[31]  S. Bustin,et al.  Improving the reliability of peer-reviewed publications: We are all in it together , 2015, Biomolecular detection and quantification.

[32]  J. Ioannidis,et al.  Reproducibility in Science: Improving the Standard for Basic and Preclinical Research , 2015, Circulation research.

[33]  E. Greenfield,et al.  Antibodies : a laboratory manual , 2014 .

[34]  P. Whitley,et al.  CiteAb: a searchable antibody database that ranks antibodies by the number of times they have been cited , 2014, BMC Cell Biology.

[35]  Francis S. Collins,et al.  Fixing problems with cell lines , 2014, Science.

[36]  E. Lundberg,et al.  Antibody performance in western blot applications is context-dependent. , 2014, Biotechnology Journal.

[37]  David L Rimm,et al.  [Letter to the Editor] The need for improved education and training in research antibody usage and validation practices. , 2016, BioTechniques.

[38]  Demin Li,et al.  The European antibody network's practical guide to finding and validating suitable antibodies for research , 2015, mAbs.

[39]  S. Goodman.  The antibody horror show: an introductory guide for the perplexed. , 2018, New biotechnology.

[40]  S. Villapol,et al.  Commercially Available Angiotensin II At2 Receptor Antibodies Are Nonspecific , 2013, PloS one.

[41]  Ulf Landegren,et al.  Strong impact on plasma protein profiles by precentrifugation delay but not by repeated freeze-thaw cycles, as analyzed using multiplex proximity extension assays , 2017, Clinical chemistry and laboratory medicine.

[42]  Maryann E. Martone,et al.  RRIDs: A Simple Step toward Improving Reproducibility through Rigor and Transparency of Experimental Methods , 2016, Neuron.

[43]  Kristina D. Micheva,et al.  Array Tomography: A New Tool for Imaging the Molecular Architecture and Ultrastructure of Neural Circuits , 2007, Neuron.

[44]  Kurt Zatloukal,et al.  Variability of protein and phosphoprotein levels in clinical tissue specimens during the preanalytical phase. , 2012, Journal of proteome research.

[45]  David E. Gloriam,et al.  ProteomeBinders: planning a European resource of affinity reagents for analysis of the human proteome , 2007, Nature Methods.

[46]  Jennifer Maynard,et al.  When monoclonal antibodies are not monospecific: Hybridomas frequently express additional functional variable regions , 2018, mAbs.

[47]  R. Santos,et al.  Validation of commercial Mas receptor antibodies for utilization in Western Blotting, immunofluorescence and immunohistochemistry studies , 2017, PloS one.